Webinar: Tumor fusion burden and the immune landscape of prostate cancer
The webinar in brief
- We discuss how immune checkpoint inhibitors have been largely unsuccessful against prostate cancer, and current biomarkers do not effectively identify those patients most likely to respond to treatment
- This presentation explores what the genetic make-up of a tumor can tell us about its immune landscape, and describes tumor fusion burden, a novel biomarker for immune cell infiltration and activation in prostate cancer
This webinar features data published on the scientific paper Cancer Immunology Research
Speaker’s biography
Lorna joined Fios Genomics in 2018 after completing a PhD in the systems biology of cancer stem cells at the Paul O’Gorman Leukaemia Research Centre in Glasgow, UK, and now works as a senior bioinformatician with the company.
During her PhD, Lorna combined computational biology with lab-based investigation of clinical samples to identify novel therapeutic targets in leukemia. Since joining Fios, she has worked extensively on projects involving biomarker discovery in clinical trials, specializing in analysis of gene expression and genome sequencing data from cancer patients.
Request a bioinformatics sample report
Our team has created a sample report based on data published from a study from Genentech, Inc. that Fios Genomics has been involved in. This study, investigating response to PD-L1 blockade therapies in patients with metastatic urothelial cancers, has been published in Nature (Mariathasan et al. Nature 2018).
The report presents a portion of the published analysis above concerning overall survival and response to treatment. We highlight the ability of high-throughput approaches to define biomarkers which accurately predict both treatment response to anti-PD-L1 therapy and overall survival in patients with metastatic urothelial cancer.
Fill the form to access the report
